Inhibikase Therapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
IKT Nasdaq 2836 www.inhibikase.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Inhibikase Therapeutics, Inc.

Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Oct 2nd, 2026 2:01 pm
Inhibikase Therapeutics Announces Second Quarter 2026 Financial Results and Highlights Recent Activity - Aug 11th, 2026 2:01 pm
Inhibikase Therapeutics Announces FDA Orphan Drug Designation Granted to IKT-001 for the Treatment of PAH - Jul 23rd, 2026 6:00 am
Inhibikase Therapeutics Announces Sale of $50 Million of Shares Through its At-the-Market (ATM) Facility - Jul 14th, 2026 6:00 am
Inhibikase Therapeutics Announces First Quarter 2026 Financial Results and Highlights Recent Activity - May 12th, 2026 2:01 pm
Inhibikase Therapeutics Announces Enrollment of First Patient in IMPROVE-PAH Global Phase 3 Study of IKT-001 in the Treatment of Pulmonary Arterial Hypertension - Apr 7th, 2026 6:00 am
Bank of America Predicts Up to 240% Jump for These 2 ‘Strong Buy’ Stocks - Feb 22nd, 2026 4:15 am
Inhibikase Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants - Nov 20th, 2025 7:54 pm